Genmab A/S Shares Outstanding History (GMAB)
Genmab A/S reported 64.2M shares outstanding at the end of fiscal 2025.
View full Genmab A/S company overviewGenmab A/S annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 64.2M | −1.9M | −2.94% |
| 2024 | 2024-12-31 | 66.2M | 112,651 | +0.17% |
| 2023 | 2023-12-31 | 66.1M | 702,910 | +1.08% |
| 2022 | 2022-12-31 | 65.4M | — | — |
| 2019 | 2019-12-31 | 65.1M | 3.6M | +5.82% |
| 2018 | 2018-12-31 | 61.5M | 311,897 | +0.51% |
| 2017 | 2017-12-31 | 61.2M | — | — |
Genmab A/S quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 61.4M | −64,876 | −0.11% |
| Q1 2026 | 2026-03-31 | 61.4M | — | — |
| Q4 2025 | 2025-12-31 | 64.2M | −1.9M | −2.94% |
| Q3 2025 | 2025-09-30 | 61.6M | — | — |
| Q2 2025 | 2025-06-30 | 61.5M | — | — |
| Q4 2024 | 2024-12-31 | 66.2M | — | — |
Genmab A/S Share Buyback History
A share buyback, also called a stock repurchase, is when a company uses cash to buy its own shares. Genmab A/S share buyback history shows the reported cash used for repurchases. Buybacks can reduce shares outstanding, but issuance, stock-based compensation, acquisitions, and stock splits can change the share count separately.
Genmab A/S used $430.0M to repurchase common stock in fy 2025. Across the latest 3 reported fiscal years, total share repurchases were $1.07B. The latest reported quarter showed $0 of share repurchases.
| Fiscal year | Period ended | Share repurchases |
|---|---|---|
| 2025 | 2025-12-31 | $430.0M |
| 2024 | 2024-12-31 | $560.0M |
| 2023 | 2023-12-31 | $81.0M |
TickerStat uses SEC-reported cash payments for common-stock repurchases. The amounts describe capital returned through buybacks; they are not a forecast or a measure of the number of shares retired.
Genmab A/S shares outstanding trends
Between the periods ended 2017-12-31 and 2025-12-31, Genmab A/S's shares outstanding moved from 61.2M to 64.2M, a change of 3.1M. The latest reported quarter, Q2 2026, shows 61.4M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Genmab A/S source filings ↗Community posts
Genmab reports mature survival data for petosemtamab in head and neck cancer
Genmab ($GMAB) reported median overall survival of 28.2 months with petosemtamab plus pembrolizumab in a Phase 2 study of previously untreated, recurrent or metastatic PD-L1-positive head and neck cancer. Among 43 patients evaluable for eff ...
Genmab and Incyte agree colorectal-cancer combination trial
Genmab ($GMAB) and Incyte ($INCY) agreed to test a three-part treatment approach in previously untreated metastatic colorectal cancer carrying a KRAS G12D mutation. The planned Phase 1/2 study combines Genmab’s petosemtamab, an antibody tar ...